Use

The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly in patients with cytogenetically normal karyotype (CN‑AML). Presence of CEBPA mutations has been associated with a favorable prognosis compared to other CN‑AML groups. Testing for CEBPA mutation, along with NPM1, is recommended for all patients with CN‑AML.